5篇
您的检索式：作者名="Jonathan Bank"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Normative Development of White Matter Tracts: Similarities and Differences in Relation to Age, Gender, and Intelligence显示文摘 | Jonathan D. Clayden Sebastian Jentschke Mónica Mu?oz Janine M. Cooper Martin J. Chadwick Tina Banks Chris A. Clark Faraneh Vargha-Khadem | 2012 | Cerebral Cortex2012，，8： | 1 |
| 2 | Multicenter, randomized, controlled trial of virtual-reality simulator training in acquisition of competency in colonoscopy显示文摘 | Jonathan Cohen Seth A. Cohen Kinjal C. Vora Xiaonan Xue J. Steven Burdick Simmy Bank Edmund J. Bini Henry Bodenheimer Maurice Cerulli Hans Gerdes David Greenwald Frank Gress Irwin Grosman Robert Hawes Gerard Mullen Felice Schnoll-Sussman Anthony Starpoli | 2006 | Gastrointestinal Endoscopy2006，，3： | 1 |
| 3 | Transport of brain-derived neurotrophic factor across the blood–brain barrier显示文摘 | Weihong Pan William A Banks Melita B Fasold Jonathan Bluth Abba J Kastin | 1998 | Neuropharmacology1998，，12： | 1 |
| 4 | Multi‐centre reproducibility of diffusion MRI parameters for clinical sequences in the brain显示文摘 | Matthew Grech‐Sollars Patrick W. Hales Keiko Miyazaki Felix Raschke Daniel Rodriguez Martin Wilson Simrandip K. Gill Tina Banks Dawn E. Saunders Jonathan D. Clayden Matt N. Gwilliam Thomas R. Barrick Paul S. Morgan Nigel P. Davies James Rossiter Dorothee | 2015 | NMR Biomed2015，，： | 1 |
| 5 | Patient-centric dose equivalency pilot study of incobotulinumtoxin a(xeomin)vs.abobotulinumtoxin a(dysport)in the treatment of glabellar frown lines显示文摘Aim:Incobotulinumtoxin A(xeomin)has been proposed as an alternative to abobotulinumtoxin A(dysport)and onabotulinumtoxin A(Botox)in the treatment of glabellar frown lines.A recent study is comparing abobotulinumtoxin A and onabotulinumtoxin A revealed equivalent efficacy with a dose conversion ratio of 2.5:1.We sought to establish effectiveness and dosing equivalency of incobotulinumtoxin A vs.abobotulinumtoxin A.Methods:Inclusion criteria for this pilot study included patients of a single surgeon(LAC)who had previously received a constant dose of abobotulinumtoxin A over at least four consecutive treatment sessions for the previous 12 months to achieve an 85-90%elimination of dynamic glabellar frown lines.The primary outcome sought dose comparison between established maintenance abobotulinumtoxin A dosing and incobotulinumtoxin A first-time dosing.A 2:1 conversion(abobotulinumtoxin A:incobotulinumtoxin A)was chosen in most patients.Secondary outcomes were patient-reported onset of effect,physician-assessed effect at 10-12 weeks,pain associated with administration,and patient perceived need for re-treatment at 2 weeks.Results:A total of 32 subjects were included.The mean dose of incobotulinumtoxin A was 17.1 units(±6.1,the median dose 20 units).The mean dose of abobotulinumtoxin A was 27.6(±11.7,the median dose 27.5 units).The mean difference in treatment units was 10.5(95%confidence interval,P<0.001).Among 30 patients who reported effect onset,the median was 8.5 days,with a range of 1-14.At 10-12 weeks,muscle paralysis was assessed to be 69.2%(±27.3),vs.90.3%(±1.8)with abobotulinumtoxin A(P<0.001).The majority of patients rated pain of administration as equal or greater to that of abobotulinumtoxin A(63%and 22%,respectively).Three patients(9%)required re-treatment at 2 weeks with abobotulinumtoxin A due to lack of effective treatment with incobotulinumtoxin A.Abobotulinumtoxin A re-treatment was chosen by the patient.Conclusion:We found incobotulinumtoxin A at 17.1(±6.1)units to be less effective than abobotulinumtoxin A at 27.6(±11.7)units in the treatment of glabellar frown lines at 10-12 weeks postadministration.Dosing was less predictable than dosing associated with abobotulinumtoxin A treatment.Larger,randomized controlled trials are indicated to further delineate these differences and to clarify whether this difference from previously published incobotulinumtoxin A dosing may have been due to the small sample size. | Jonathan Bank Nicole A.Phillips Laurie A.Casas | 2015 | Plastic and Aesthetic Research2015，2，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员